Own-brand manufacturing: Enzakar® 40mg enzalutamide
Towada Products · New Delhi, India · Updated October 2026
Beyond trading established brands, Towada is building its own manufactured product line, starting in oncology.
Towada Products · New Delhi, India · Updated October 2026
Beyond trading established brands, Towada is building its own manufactured product line, starting in oncology.

Enzakar® 40mg is our first own-brand product: enzalutamide capsules, an oncology medicine in the androgen receptor inhibitor class. Each pack holds 4×28 hard gelatin capsules for oral use, to be stored below 30°C.
Enzakar® is manufactured under contract to Towada's specification and quality requirements. It is a prescription medicine, to be sold by retail only on the prescription of a registered oncologist. Enzakar® is currently marketed in India.
Enzalutamide is approved by regulators including the US FDA and the EMA for forms of advanced prostate cancer. The drug class, approved indications and every enzalutamide brand we export are set out on our enzalutamide molecule page. We also export other established enzalutamide brands alongside Enzakar®.
We are interested in hearing from licensed distributors and institutions in our export markets who would like to discuss Enzakar®, or future own-brand products in oncology and our other core therapy areas. Tell us your market, your licence status and the volumes you have in mind. Whether a product can be imported into a given country depends on that country's regulator, and we will tell you plainly what applies before any order is placed.
Distributors who already buy oncology medicines from our export business can add Enzakar® to the same enquiry. We send product details and the documents available for it on request, and our team stays in contact for follow-up and repeat orders.
Tell us your country, your licence status and the quantity you have in mind. Prefer to message directly? WhatsApp +91 99995 62955 or email H.S.Gandhi@towadaproducts.in.